Elutia Inc (ELUT) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Elutia Inc   (NASDAQ: ELUT)


Elutia Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Elutia Inc's ROI in the third quarter of 2026?
Elutia Inc achieved a return on average invested assets (ROI) of 163.14 % in its third quarter of 2026, this is above ELUT's average return on investment of -173.76%.
Elutia Inc invested over the 12 months ending in its third quarter of 2026 $33 million

ROI fell compared to the second quarter of 2026, despite the net income growth of % from the second quarter of 2026.

Within the Healthcare sector 2 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 18 to 19.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 87064.71 % 519.06 % 323.7 % 573.16 % -98.2 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 32 23 37 42 -6
Return On Investment (TTM) 163.14 % 218.66 % 275.12 % 491.62 % -
ELUT's Overall Ranking # 19 # 18 # 4546 # 4471 # 4622
Seq. Investment Change TTM 40.72 % 30.78 % 66.86 % 28286.93 % -99 %
Seq. Net Income Change TTM 4.99 % 3.94 % -6.62 % - -
Net Income (TTM) in Millions 54 52 50 53 -26

ELUT Company Profile >> Back to ELUT Roi Comparisons >> See Annual ELUT Return On Investment



Return On Investment ELUT's Ranking
Within: No.
Industry # 2
Sector # 3
Overall # 19

Return On Investment Statistics
High Average Low
386.83 %
-173.76 %
-743.67 %
(Dec 31 2025)   (Jun 30 2024)







Financial Statements
Elutia Inc's III. Quarter Investments $ 32 Millions ELUT's Balance sheet
Elutia Inc's III. Quarter Income $ -1 Millions Quarterly ELUT's Income Statement
ELUT's Income by Division See ELUT's Income by Division


ELUT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 37 -2 0 26 25
Y / Y Investment Growth - - -98.51 % 6.48 % -37.49 %
Net Income in Millions 53 -54 -38 -33 -25
Y / Y Net Income Growth - - - - -
Annual Return On Investment 143.45 % - -9630.69 % -125.44 % -100.82 %


Annual Roi Comment
In the fiscal year 2025 ROI deteriorated to 143.45 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ELUT's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ELUT's Competitors
Subscribers only: Roi for Elutia Inc's Suppliers
Subscribers only: Return On Investment for ELUT's Customers

Other Ratios
ELUT's Roa ELUT's Inventory Turnover Ratio ELUT's Growth Rates ELUT's Dividend Statistics
ELUT's Profitability Ratios ELUT's Asset Turnover Ratio ELUT's Dividend Growth
ELUT's Roe ELUT's Valuation Ratios ELUT's Financial Strength Ratios ELUT's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Stablecoin Development Corporation  428.88 %
Vor Biopharma Inc   293.36 %
Elutia Inc   152.93 %
Arbutus Biopharma Corp  120.80 %
Indivior Pharmaceuticals Inc   108.22 %
Lensar Inc   94.32 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %

Date modified: 2026-11-11T13:41:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.